{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:07:00Z","timestamp":1792480020557,"version":"4.5.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Conventional disproportionality analysis assumes comparable background event rates between case and control cohorts. In patients with primary endocrine malignancies treated with immune checkpoint inhibitors (ICIs), this assumption fails: disease-inherent hormonal dysregulation and therapy-related sequelae inflate background event rates and may produce signals misattributed to ICI exposure. No prior study has used tumor-type-specific reference populations to separate drug-attributable from disease-inherent signals in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Forty quarterly FAERS cycles (Q1 2015 to Q4 2024) were analyzed after deduplication of 2,264,070 reports. In a pooled analysis, 329 ICI-treated endocrine cancer cases were compared with 80,191 ICI-treated non-endocrine cancer controls across six pre-specified endocrine immune-related adverse event categories, with false discovery rate (FDR) correction. The central step was a confounding-aware reanalysis comparing ICI-exposed patients of a given tumor type against a reference cohort with the same malignancy but no ICI exposure, using logistic regression adjusted for age and sex. The thyroid carcinoma association was tested using reporter type, Firth penalized regression, multiple imputation, and a tipping-point analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pooled adrenal insufficiency did not reach the signal threshold after FDR correction (ROR = 1.922; 95% CI 1.051\u20133.513; q = 0.143). This non-significance concealed two opposing patterns. In ACC, adrenal insufficiency was the strongest uncorrected subgroup signal yet was not associated with ICI exposure after adjustment (OR = 0.58; 95% CI 0.09\u20131.95); with four exposed events and 12.6% power, this subgroup cannot confirm or exclude an association. In thyroid carcinoma, ICI exposure showed markedly higher adrenal insufficiency reporting odds (OR = 13.33; 95% CI 4.81\u201331.85), remaining positive under reporter adjustment, Firth regression, and multiple imputation, with a tipping-point analysis indicating only implausibly extreme confounding could nullify it.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pooled pharmacovigilance can misclassify drug-attributable and disease-inherent events. Tumor-type-specific reference modeling separates them: ACC data are most consistent with disease-inherent pathophysiology, whereas thyroid carcinoma shows a robust adrenal insufficiency signal. We interpret the thyroid signal as hypothesis-generating, since differential endocrine surveillance may contribute to its magnitude, and prospective validation is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1868030","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:26:56Z","timestamp":1782192416000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Confounding-aware disproportionality analysis reveals disease-inherent versus drug-attributable endocrine safety signals of immune checkpoint inhibitors"],"prefix":"10.3389","volume":"17","author":[{"given":"Osman Bilge","family":"Kaya","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refika","family":"Yorulmaz Kaya","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Gazi University Faculty of Medicine","place":["Ankara, T\u00fcrkiye"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"B4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"T331","DOI":"10.1530\/ERC-17-0358","article-title":"Endocrine side effects of cancer immunotherapy","volume":"24","author":"Cukier","year":"2017","journal-title":"Endocr. Relat. Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e91730","DOI":"10.7759\/cureus.91730","article-title":"Checkpoint on adrenal insufficiency: optimizing screening in immune checkpoint inhibitor therapy","volume":"17","author":"Darapu","year":"2025","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the european network for the study of adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur. J. Endocrinol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1097\/MED.0000000000000570","article-title":"Hashimoto's thyroiditis as a risk factor for thyroid cancer","volume":"27","author":"Feldt-Rasmussen","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"B9","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO VigiBase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"key":"B10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"498","DOI":"10.21873\/cdp.10246","article-title":"Hypothyroidism with ACTH deficiency during pembrolizumab therapy for lung cancer: case report and literature review","volume":"3","author":"Hashinokuchi","year":"2023","journal-title":"Cancer diagn. Progn."},{"key":"B12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1530\/EJE-09-0044","article-title":"Polyglandular autoimmune syndromes","volume":"161","author":"Kahaly","year":"2009","journal-title":"Eur. J. Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1908771","DOI":"10.1080\/2162402X.2021.1908771","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538","volume":"10","author":"Klein","year":"2021","journal-title":"Oncoimmunology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.3390\/cancers15072016","article-title":"The uncharted landscape of rare endocrine immune-related adverse events","volume":"15","author":"Mytareli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1097\/CCO.0000000000000150","article-title":"Association of hashimoto's thyroiditis and thyroid cancer","volume":"27","author":"Noureldine","year":"2015","journal-title":"Curr. Opin. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13256-019-2002-2","article-title":"Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature","volume":"13","author":"Ohara","year":"2019","journal-title":"J. Med. Case Rep."},{"key":"B19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11523-019-00632-w","article-title":"Toxicities with immune checkpoint inhibitors: emerging priorities from disproportionality analysis of the FDA adverse event reporting system","volume":"14","author":"Raschi","year":"2019","journal-title":"Target. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B23","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"B25","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","article-title":"Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review","volume":"9","author":"Stelmachowska-Bana\u015b","year":"2020","journal-title":"Endocr. Connect."},{"key":"B26","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"B27","first-page":"376","article-title":"Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review","volume":"67","author":"Van den Driessche","year":"2009","journal-title":"Neth. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Drug Saf."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e403","DOI":"10.3275\/7870","article-title":"Is diffuse and peritumoral lymphocyte infiltration in papillary thyroid cancer a marker of good prognosis?","volume":"34","author":"Villagelin","year":"2011","journal-title":"J. Endocrinol. Invest."},{"key":"B30","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"e2118526","DOI":"10.1001\/jamanetworkopen.2021.18526","article-title":"Prevalence of Hashimoto thyroiditis in adults with papillary thyroid cancer and its association with cancer recurrence and outcomes","volume":"4","author":"Xu","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"750","DOI":"10.3803\/EnM.2023.1785","article-title":"Incidence of endocrine-related dysfunction in patients treated with new immune checkpoint inhibitors: a meta-analysis and comprehensive review","volume":"38","author":"Yoo","year":"2023","journal-title":"Endocrinol. Metab. Seoul."},{"key":"B34","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US food and drug administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J. Immunother. Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1868030\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T05:26:58Z","timestamp":1782192418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1868030\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":34,"alternative-id":["10.3389\/fphar.2026.1868030"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1868030","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1868030"}}